Infantile hypercalcemia with novel compound heterozygous mutation in SLC34A1 encoding renal sodium-phosphate cotransporter 2a: a case report
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Idiopathic infantile hypercalcemia is characterized by hypercalcemia, dehydration, vomiting, and failure to thrive, and it is due to mutations in 24-hydroxylase (CYP24A1). Recently, mutations in sodium-phosphate cotransporter (SLC34A1) expressed in the kidney were discovered as an additional cause of idiopathic infantile hypercalcemia. This report describes a female infant admitted for evaluation of nephrocalcinosis. She presented with hypercalcemia, hypercalciuria, low intact parathyroid hormone level, and high 1,25-dihydroxyvitamin D3 level. Exome sequencing identified novel compound heterozygous mutations in SLC34A1 (c.1337G>A, c.1483C>T). The patient was treated with fluids for hydration, furosemide, a corticosteroid, and restriction of calcium/vitamin D intake. At the age of 7 months, the patient's calcium level was within the normal range, and hypercalciuria waxed and waned. Renal echogenicity improved on the follow-up ultrasonogram, and developmental delay was not noted. In cases of hypercalcemia with subsequent hypercalciuria, DNA analysis for SLC34A1 gene mutations and CYP24A1 gene mutations should be performed. Further studies are required to obtain long-term data on hypercalciuria and nephrocalcinosis.
Abstract
Idiopathic infantile hypercalcemia is characterized by hypercalcemia, dehydration, vomiting, and failure to thrive, and it is due to mutations in 24-hydroxylase (CYP24A1). Recently, mutations in sodium-phosphate cotransporter (SLC34A1) expressed in the kidney were discovered as an additional cause of idiopathic infantile hypercalcemia. This report describes a female infant admitted for evaluation of nephrocalcinosis. She presented with hypercalcemia, hypercalciuria, low intact parathyroid hormone level, and high 1,25-dihydroxyvitamin D3 level. Exome sequencing identified novel compound heterozygous mutations in SLC34A1 (c.1337G>A, c.1483C>T). The patient was treated with fluids for hydration, furosemide, a corticosteroid, and restriction of calcium/vitamin D intake. At the age of 7 months, the patient's calcium level was within the normal range, and hypercalciuria waxed and waned. Renal echogenicity improved on the follow-up ultrasonogram, and developmental delay was not noted. In cases of hypercalcemia with subsequent hypercalciuria, DNA analysis for SLC34A1 gene mutations and CYP24A1 gene mutations should be performed. Further studies are required to obtain long-term data on hypercalciuria and nephrocalcinosis.
참고문헌 (17)
- Lightwood R, "Idiopathic hypercalcaemia in infants", Lancet, 265, pp.255~256 (1953)
- Koltin D, "Mild infantile hypercalcemia: diagnostic tests and outcomes", J Pediatr, 159, pp.215~221.e1 (2011)
- Schlingmann KP, "Mutations in CYP24A1 and idiopathic infantile hypercalcemia", N Engl J Med, 365, pp.410~421 (2011)
- Schlingmann KP, "Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia", J Am Soc Nephrol, 27, pp.604~614 (2016)
- Rajagopal A, "Exome sequencing identifies a novel homozygous mutation in the phosphate transporter SLC34A1 in hypophosphatemia and nephrocalcinosis", J Clin Endocrinol Metab, 99, pp.E2451~E2456 (2014)
- Prie D, "Genetic disorders of renal phosphate transport", N Engl J Med, 362, pp.2399~2409 (2010)
- Wagner CA, "The SLC34family of sodium-dependent phosphate transporters", Pflugers Arch, 466, pp.139~153 (2014)
- Perwad F, "Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxy-vitamin D metabolism in mice", Endocrinology, 146, pp.5358~5364 (2005)
- Wang W, "Reduced expression of Na-K-2Cl cotransporter in medullary TAL in vitamin D-induced hypercalcemia in rats", Am J Physiol Renal Physiol, 282, pp.F34~F44 (2002)
- Ronnefarth G, "Nephrocalcinosis in children: a retrospective survey. Members of the Arbeitsgemeinschaft fur padiatrische Nephrologie", Pediatr Nephrol, 14, pp.1016~1021 (2000)
- Halbritter J, "Fourteen monogenic genes account for 15% of nephrolithiasis", nephrocalcinosis, 2015, pp.26, 543~551
- Lapointe JY, "NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak", Kidney Int, 69, pp.2261~2267 (2006)
- Rodd C, "Hypercalcemia of the newborn:etiology, evaluation, and management", Pediatr Nephrol, 13, pp.542~547 (1999)
- Fencl F, "Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1gene", Eur J Pediatr, 172, pp.45~49 (2013)
- Marks BE, "Idiopathic infantile hypercalcemia:case report and review of the literature", J Pediatr Endocrinol Metab, 29, pp.127~132 (2016)
- Habbig S, "Nephrocalcinosis and urolithiasis in children", Kidney Int, 80, pp.1278~1291 (2011)
- Odvina CV, "Long-term combined treatment with thiazide and potassium citrate in nephrolithiasis does not lead to hypokalemia or hypochloremic metabolic alkalosis", Kidney Int, 63, pp.240~247 (2003)